The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
Portfolio Pulse from Benzinga Newsdesk
The FDA has cleared C4 Therapeutics' Investigational New Drug Application for CFT8919, a treatment for non-small cell lung cancer. C4T plans to initiate trials outside Greater China after Betta Pharmaceuticals concludes its Phase 1 dose escalation study in the region.
July 05, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
C4 Therapeutics' IND Application for CFT8919 has been cleared by the FDA, paving the way for trials outside Greater China after Betta Pharmaceuticals' Phase 1 study.
The FDA clearance of C4 Therapeutics' IND Application for CFT8919 is a significant regulatory milestone for the company. This could potentially lead to a positive market reaction, as it allows the company to proceed with trials outside Greater China, expanding the potential market for the drug.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100